Novel iron-containing phosphate binders for treatment of hyperphosphatemia.

about

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide Comment on: "Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode".

P2860

Q26764806-69FB3301-185C-439E-B16B-A748AD4620B1 Q42370954-011B6746-F5F7-4FAD-8865-2E75309489C2

P2860

Novel iron-containing phosphate binders for treatment of hyperphosphatemia.

Item

http://www.wikidata.org/entity/Q38570622

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Novel iron-containing phosphate binders for treatment of hyperphosphatemia.

@en

type

Item

label

Novel iron-containing phosphate binders for treatment of hyperphosphatemia.

@en

prefLabel

Novel iron-containing phosphate binders for treatment of hyperphosphatemia.

@en

P1476

Novel iron-containing phosphate binders for treatment of hyperphosphatemia.

@en

P2093

Holger Schmid

http://www.w3.org/2001/XMLSchema#string

Stephan R Lederer

http://www.w3.org/2001/XMLSchema#string

P2860

Oral phosphate binders in patients with kidney failure

Ferric citrate controls phosphorus and delivers iron in patients on dialysis.

A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease.

No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease.

Different Mg to Fe ratios in the mixed metal MgFe hydroxy-carbonate compounds and the effect on phosphate binding compared with established phosphate binders.

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

Serum phosphate and mortality in patients with chronic kidney disease

Chewability testing in the development of a chewable tablet for hyperphosphatemia.

Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity.

The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro.

P304

2179-2191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2015.1079622

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281146368

http://www.w3.org/2001/XMLSchema#string

P698

26293683

http://www.w3.org/2001/XMLSchema#string

Novel iron-containing phosphate binders for treatment of hyperphosphatemia.

about

P2860

P2860

Novel iron-containing phosphate binders for treatment of hyperphosphatemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698